Supplemented and unsupplemented tissue sealants, methods of their production and use

Abstract

This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation-in-Part Application of U.S. application Ser. No. 08 / 351,006, filed Dec. 7, 1994, abandonded, which is a Continuation-in-Part Application of U.S. application Ser. No. 08 / 328,552, filed Oct. 25, 1994, abandoned, which is a Continuation Application of U.S. application Ser. No. 08 / 031,164, filed Mar. 12, 1993, abandoned, which is a Continuation-in-Part Application of U.S. application Ser. Nos. 07 / 618,419 and 07 / 798,919, filed Nov. 27, 1990, and Nov. 27, 1991, respectively, both of which are abandoned, all of which are herein incorporated by reference.RIGHTS OF THE UNITED STATES GOVERNMENT IN THIS INVENTION[0002]Under a Cooperative Research and Development Agreement between The American National Red Cross and The U.S. Army Institute of Dental Research, the U.S. Government may have a non-exclusive, irrevocable, paid-up license in one or more embodiments of this invention.FIELD OF INVENTION[0003]This invention ...

AI Technical Summary

Benefits of technology

[0087]A third advantage of the present invention is that animal cells can migrate into and through, and grow in the TSs of the present invention. This aids engraftment of the cells to neighboring tissues and prostheses. Based on the composition of the TSs which are available in Europe, it is expected that this is not possible with these formulations. Instead, animal cells must migrate around or digest commercially available TS. Since the importation into the U.S. of commercially available TSs from Europe is illegal (their use in the U.S.A. has not been approved by the U.S. FDA).

Problems solved by technology

However, it has not been established if any FGF growth factor is chemotactic for fibroblasts.

However, their use to promote wound healing has yielded inconsistent results (see, e.g., Carter et al., in Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications, Alan R. Liss, Inc., New York, N.Y., pp.

The reasons for such inconsistent results are not known, but might be the result of difficulty in applying growth factors to a wound in a manner in which they can exhibit their normal array of biological activities.

However, this heat inactivation method may produce denatured proteins in the FG which may also be allergenic.

In addition, there is concern that this inactivation method will not inactivate prions which cause bovine spongiform encephalopathy, “mad cow disease,” which may be present in the TS due to the use of bovine proteins therein.

Although FG maintains hemostasis and reduces blood loss, it has not yet been shown to possess true wound healing properties.

Unfortunately, DBM materials have little clinical use unless combined with particulate marrow autografts.

There is a limit to the quantity of DBM that can be surgically placed into a recipient's bone to produce a therapeutic effect.

Soft-tissue collapse into the wound bed may likewise inhibit the proper migration of osteocompetent stem cells into the wound bed.

However, DBM in powder form is difficult to use.

Therefore, these results are inconsistent and confusing.

However, commercially available preparations of FG and other TSs are too dense to allow cell migration into and through them.

This limits their effectiveness in some in vivo uses.

However, the source of bone autografts is usually limited and the use of allogeneic bones involves a high risk of viral contamination.

However, one general problem with these techniques is that nonautologous cells were used for the seeding (see, e.g., Schrenk et al., supra) thus raising the possibility of tissue rejection.

In addition, a confluent endothelium is usually never established and requires months to do so if its.

As a result of this delay, there is a high occlusion rate of vascular prostheses (see, e.g., Zilla et al., supra).

These growth factors have not been used successfully to direct the growth of a new blood vessel(s) at a given site in vivo.

The problem after systemic administration usually lies in the low concentration of the antimicrobial agent which can be achieved at the target site.

To raise the local concentration a systemic dose increase may be effective but also may produce toxicity, microbial resistance and drug incompatibility.

To circumvent some of these problems, several alternative methods have been devised but none are ideal.

This interference limited the amount and concentration of the TET HCl that could be achieved in the AB-FG mixture and appeared to be AB concentration dependent.

However, there is little or no control over the duration of the drug release which apparently is at least partially a reflection of the relatively short life of the drug-supplemented FG.

Despite continued advances in trauma care, a significant percentage of the population, both military and civilian, suffer fatal or severe hemorrhage every year.

When severe natural or man-made disasters, local hospitals and clinics may be overwhelmed by the number of individuals requiring trauma case.

Combined with the isolating effects of such disasters, the resulting demand for blood and blood products often exceeds the locally available supplies.

In many cases, the demand upon the local medical personnel also exceeds the availed number of trained individuals.

Unfortunately, however, each of these treatments requires continuous monitoring and attention.

Images